LC-REVITALIZE: A Long Covid Repurposed Drug Study
This study, called LC-REVITALIZE, is looking for adults aged 18 to 65 who have had Long Covid for at least three months. It's testing two existing drugs, pirfenidone and upadacitinib, to see if they can help improve Long Covid symptoms. You would receive either pirfenidone, upadacitinib, or a placebo (an inactive substance that looks like the study drug). The main goal is to see if these treatments can improve symptoms like fatigue, breathing problems, memory issues, muscle/joint pain, and circulation. Researchers also want to see if the drugs reduce inflammation and are safe. This study is currently recruiting participants.
- Study design
- This is a Phase III, double-blind (neither you nor your doctor will know if you're getting the study drug or placebo), placebo-controlled study involving about 348 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- You would be followed for at least 6 months after enrollment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study
At a glance
Conditions
NCT06928272
Where you'd take part
This study runs at 9 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Centre de Recherche du CHUS (CRCHUS)
Sherbrooke, Quebec, Canadano site contact published
Recruiting
Ini-Fiocruz
Rio de Janeiro, Rio de Janerio, Brazilno site contact published
Recruiting
INMI Lazzaro Spallanzani IRCCS
Roma, Roma, Italyno site contact published
Not yet recruiting
Institut de Recherches Cliniques de Montréal (IRCM)
Montreal, Quebec, Canadano site contact published
Recruiting
Joint Clinical Research Centre (JCRC)
Kampala, Kampala, Ugandano site contact published
Not yet recruiting
Laura Rodriguez Research Institute
San Diego, Californiano site contact published
Recruiting
Sapienza Università di Roma
Roma, Roma, Italyno site contact published
Not yet recruiting
Università degli Studi di Modena e Reggio Emilia
Modena, Italyno site contact published
Not yet recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Douglas D Fraser, MD, PhD, FRCPC · PRINCIPAL_INVESTIGATOR · Western University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Symptom Burden Questionnaire (SBQ) SubscalesThe Phase 1 time frame is from enrollment on Day 1 through to the end of follow-up at Month 6, and the Phase 2 time frame will be determined based on the results of Phase 1.
The aim of this study is to evaluate the efficacy of two repurposed drugs in reducing symptom severity in participants with Long Covid. The change in symptom score (transformed scale of 0-100) from baseline to both the interim and final analyses will be compared across one of the five validated subscales, relative to the placebo. This study will utilize five validated subscales: 1) Fatigue, 2) Breathing, 3) Memory, Thinking, and Communication, 4) Muscles and Joints, and 5) Circulation. Each subscale is based on a 4-point ordinal scale that assesses frequency, severity, or interference, or it uses a dichotomous yes/no response. The subscale with the highest symptom burden, determined by the highest transformed symptom score (ranging from 0 to 100, with a higher score indicating greater symptom burden) at baseline, will be selected for evaluating treatment effects.